With US Food and Drug Administration approval for Bristol Myers Squibb Company’s Reblozyl (luspatercept) as a first-line treatment for anemia in patients with very low- to intermediate-risk myelodysplastic syndromes (MDS), EVP and chief commercialization officer Adam Lenkowsky noted in an interview with Scrip, the company’s forecast of $4bn-plus in non-risk-adjusted sales for the erythroid maturation agent by 2029 is largely de-risked, now that the product is cleared in its biggest market to date.
The FDA approved Reblozyl to treat transfusion-dependent MDS-associated anemia, regardless of patients’ ring sideroblast (RS) status and prior to erythropoiesis-stimulating...
